Author

Gabrielle Glick

Institution: Seres Therapeutics (United States)

Observed institutions: Biogen (United States), Seres Therapeutics (United States)

OpenAlex ID: A5040423986

A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology

2011 · Xiao Hu, Larisa Miller, et al. · The Journal of Clinical Pharmacology · 118

PEGylated Interferon Beta-1a: Meeting an Unmet Medical Need in the Treatment of Relapsing Multiple Sclerosis

2010 · Darren P. Baker, Robert Blake Pepinsky, et al. · Journal of Interferon & Cytokine Research · 38

Preliminary Results of the Open-Label Phase of a 2-Part Phase 1b Study That Evaluates Safety, Tolerability, Pharmacokinetics, and Efficacy of Investigational Microbiome Therapeutic SER-155 in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (allo-HCT)

2024 · Doris M. Ponce, Satyajit Kosuri, et al. · Transplantation and Cellular Therapy · 4

Pharmacokinetic, pharmacodynamic, and safety profiles of PEGylated interferon beta-1a in healthy volunteers: Results from two Phase 1 clinical studies

2009 · Gudarz Davar, Sandra Richman, et al. · Cytokine · 2

Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation

2023 · Doris M. Ponce, Satyajit Kosuri, et al. · Blood · 1

S30 A Phase 2b Study to Evaluate the Efficacy and Safety of Investigational Microbiome Therapeutic SER-287 in Mildly-to-Moderately Active UC

2022 · Brian Feagan, David Rubin, et al. · The American Journal of Gastroenterology · 1

Works count: 6

Citation count: 164

H-index: 3

I10-index: 2